Chemotherapy-Induced Neutropenia (CIN) Treatment Market: Introduction
- Loss of neutrophils causes disruption of immune defense mechanisms and increases the likelihood for infections. Neutropenia is frequently associated with cancer chemotherapy and developed by majority of cancer patients during chemotherapy.
- Chemotherapy treatments for cancer are well-known to be associated with a depletion of white blood cells, in particular neutrophils, causing a condition known as chemotherapy- -induced neutropenia (CIN)
- Chemotherapy-induced neutropenia (CIN) is the primary dose-limiting toxicity in patients with cancer treated with chemotherapy
- There are ways to manage CIN such as delaying and reducing chemotherapy treatment with hematopoietic growth factors and with intravenous antibiotic therapy
Key Drivers and Restraints of Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market
- Rise in prevalence of cancer across the globe and increase in use of chemotherapy are major drivers of the global chemotherapy-induced neutropenia (CIN) treatment market
- For instance, as per Glubocan data, total 1,80,78,957 new cancer patients were reported to suffer any form of cancer across the globe
- Robust R&D activities by major companies in the development of novel therapeutics is also fueling the global chemotherapy-induced neutropenia (CIN) treatment market
- Moreover, an increase in government funding for life-threatening diseases across the world is also a key factor driving the global chemotherapy-induced neutropenia (CIN) treatment market
Antibiotic Therapy Segment Dominated Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market
- In terms of type, the global chemotherapy-induced neutropenia (CIN) treatment market can be divided into antibiotic therapy, colony-stimulating factor therapy, granulocyte transfusion, splenectomy procedure, and others
- The antibiotic therapy accounted for a major share of the global market in 2019 owing to quicker action, high range availability, and launch of new products in the last few years
Online Pharmacies Segment to Witness Significant Growth
- In terms of distribution channel, the global chemotherapy-induced neutropenia (CIN) treatment market can be categorized into hospital pharmacies, retail pharmacies, and online pharmacies
- The retail pharmacies segment held a major share of the global market, in terms of revenue, in 2019. The trend is expected to continue during the forecast period. Inclusion of various medicines under the OTC category and preference for self-medication are projected to drive the segment.
- However, the online pharmacies segment is likely to expand at a notable CAGR from 2020 to 2030 due to an increase in Internet penetration and smartphone ownership along with the ease of ordering medications through an e-commerce platform, and better discounted rates
North America to Dominate Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market
- In terms of region, the global chemotherapy-induced neutropenia (CIN) treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
- In terms of revenue, North America dominated the global chemotherapy-induced neutropenia (CIN) treatment market in 2019 due to a rise in prevalence of different types of cancer, rise in government funding for research, and increase in cases of chemotherapy induced side-effects among cancer survivors
- For instance, as per National Cancer Institute, around 1,806,590 new cases of cancer are estimated to be diagnosed in the U.S. in 2020
- Asia Pacific is likely to be a highly lucrative market for chemotherapy-induced neutropenia (CIN) treatment during the forecast period. The market in the region is projected to expand at a high CAGR from 2020 to 2030.
- Higher patient population, adoption of new treatment methods, pipeline drugs, and increase in awareness regarding chemotherapy-induced neutropenia (CIN) are anticipated to propel the market in Asia Pacific during the forecast period
Key players Operating in Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market
The global chemotherapy-induced neutropenia (CIN) treatment market was highly fragmented in 2019. Key players operating in the global market are:
- Amgen, Inc
- Novartis AG
- Sanofi
- Biogenomics Limited
- Baxter International
- Dr. Reddy’s Laboratory Ltd.
- Apotex, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Ligand Pharmaceuticals, Inc.
- Coherus BioSciences, Inc.
Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market: Research Scope
Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Type
- Antibiotic Therapy
- Colony-Stimulating Factor Therapy
- Granulocyte Transfusion
- Splenectomy Procedure
- Others
Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Region
- North America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Interested in this report?
Get a FREE Brochure now!
